Immunotherapy and Immune Responses

This study shows that aged mice have reduced accumulation of small antigens in B cell follicles, potentially affecting vaccine responses.

This study identifies PRAME as a therapeutic target in NUT carcinoma, showing its high expression and susceptibility to T-cell mediated cytotoxicity via PRAME epitopes presented by HLA Class I molecules.

This paper redirects cytomegalovirus (CMV)-specific T cells to target pancreatic cancer, showing improved tumor control and survival in mice.

The paper shows Vγ1+ γδ T cells produce IL-4 to activate DC and CD8 T cells, enhancing immunity against Plasmodium.

The paper shows that fetal thymic expression of tumor-associated antigens (TAAs) predicts their immunogenicity and guides rational antigen selection for immunotherapy.

The paper develops a dual-antigen DNA vaccine, CaVac OPT, which enhances anti-tumor immunity in oral cancer by reprogramming the tumor microenvironment and improving response to anti-PD1 therapy.

This study demonstrates that Prime-Target neoantigen vaccination effectively overcomes immunosuppression in 'cold' tumors by enhancing T cell infiltration and reshaping the tumor microenvironment.

This study compares multimerization domains in mRNA LNP vaccines, finding that IMX313 enhances antibody responses more than other domains.

The paper identifies seven thymic conventional dendritic cell subsets and their distinct functional roles and dependencies on thymocyte subsets for homeostasis and activation.

This paper demonstrates that ALTA(R) vaccine particles provide sustained antigen release, improving immune response to single-shot vaccination compared to liquid regimens.

This study uses single-cell RNA sequencing to classify and characterize dendritic cell subsets in equine blood, identifying new subclusters and confirming known phenotypes across species.

This paper develops a scalable method to generate pure CD103+ cDC1 from mouse bone marrow cultures, achieving high purity and yield for immunological studies.

The paper demonstrates that delivering FLT3L with CXCL9 and CCL5 enhances cDC1 infiltration and antitumor immunity in mice and humanized models.

This study identifies a combination of adjuvants that enhance the immunogenicity of naked mRNA vaccines delivered by jet-injection, achieving protection against SARS-CoV-2 and influenza with reduced reactogenicity.

This study shows that NLRC5 expression in tumor cells enhances MHC-I and promotes antitumor immunity by activating immune cells and shaping the tumor microenvironment.

This study shows CD74 deletion enhances dendritic cell function and tumor immunogenicity in melanoma, improving immune checkpoint therapy outcomes.

This study demonstrates a method to generate antigen-presenting vesicles displaying pMHCI using engineered constructs, which selectively stimulate T cells for potential cell-free immunotherapy.

The paper demonstrates that T cells from 72% of individuals mount a specific response against Mesothelin, showing cytotoxicity and anti-tumor effects in 3D models.

The paper identifies cryptic leukemia antigens that share homology with microbial epitopes and can stimulate T-cell responses in healthy donors, suggesting their potential as targets for T-cell-based immunotherapies.

This study shows that breast tumors impair antigen presentation in local lymph nodes, which can be overcome by delivering IL1β or adjuvants to distant lymph nodes, improving anti-cancer immune responses.

This study identifies that cancers limit p53 neoantigen display on MHC molecules, evading T cell detection through immune selection and ERAP1-mediated destruction.

This study investigates antibody responses to melanoma helper peptide vaccines, showing polyclonal responses and IgG subclass variations influenced by adjuvant type.

This paper shows that dendritic cells use virus-like vesicles to enhance antigen presentation and T cell activation, leading to improved cancer vaccination.

This study develops a neoantigen-microbead platform for personalized T cell cancer vaccination and shows it effectively inhibits tumor growth in a mouse model.

This paper develops a PBPK model to optimize cancer vaccine design by simulating antigen transport and immune responses across organs.

The paper identifies Grem1-expressing fibroblastic reticular cells as a source of FLT3L that supports dendritic cell homeostasis and function in lymph nodes.

This study shows that repeated RNA-lipoplex vaccination sustains functional CD8 T cells in tumors and improves therapeutic outcomes.

This paper develops a viral capsid-based vaccine platform using MS2 virus to display peptide antigens, demonstrating effective T-cell activation and MHC presentation in vitro.

This study generates and matures bone marrow-derived dendritic cells in vitro using STING activation to enhance CD8 T cell priming.